Pancreatic cancer is the most dangerous cancer in the world. The most common form of pancreatic cancer is PDAC, the five-year survival rate of which is 8%. It is difficult to detect PDAC because of the anatomically inaccessible location of the pancreas and difficult to cure PDAC because it is chemo- and radioresistant. Surgery is the only method to achieve a complete cure. Promisingly, olaparib, an inhibitor of PARP, is the newest standard for BRCA1/2-mutant pancreatic cancer patients .